MIS416

MIS416 is an experimental drug developed by Innate Immunotherapeutics which underwent clinical trials to treat secondary progressive multiple sclerosis. It is derived from the bacteria that causes acne and targets myeloid cells through TLR9 and NOD2.[1][2][3][4] In one of its first rounds of clinical trials, the drug was shown to be "safe and well tolerated", with 80% of secondary-progressive multiple sclerosis patients exhibiting more than 30% improvement in at least one area of their MS status.[1] However, Phase II clinical trials were unable to prove that the drug provided a benefit to patients. It is also being researched as a potential treatment for cancer.

  1. ^ a b "Innate Immunotherapeutics: Acne Offers Real Hope for MS Treatment". Australasian Biotechnology. 23 (3): 55. October 2013. ISSN 1036-7128.
  2. ^ "Drug Profile: MIS 416". adisinsight.springer.com. 27 June 2018. Retrieved 29 August 2018.
  3. ^ "Results Announced from Phase 2 Trial of MIS416". National Multiple Sclerosis Society. 27 June 2017.
  4. ^ "Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis". United States National Library of Medicine. 28 August 2014. Retrieved 29 August 2018.